Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
Riccardo Menandro, Pharmaceutical Scientific Reporter at Maven Pharma, shared on LinkedIn:
”Most conversations about lipid nanoparticles focus on the science.
This one focuses on the decisions.
LNP technology has moved from research platform to clinical mainstream faster than almost any other delivery system in recent memory.
Patisiran demonstrated hepatic gene silencing at therapeutic scale.
The COVID-19 vaccines demonstrated industrial scalability.
The pipeline now spans oncology, rare disease, hemophilia, and in vivo CRISPR editing.
But for organizations building or evaluating LNP-based programs, the scientific opportunity is only part of the picture.
Formulation expertise, IP position, tissue targeting strategy, and regulatory engagement are the variables that determine whether a program reaches the clinic on a competitive timeline, or doesn’t.
This white paper examines all four, with a focus on the decisions that matter most at the development planning stage.
Full document attached.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026